Acquisitions23 Dec 2025, 09:11 am
Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab
AI Summary
Biocon Biologics Limited, a fully integrated global biosimilars company, has secured full and exclusive global rights for Hulio® (biosimilar Adalimumab) from Fujifilm Kyowa Kirin Biologics Co., Ltd. The company will now have end-to-end responsibility for manufacturing and commercialization along with rights for any additional development activities. The new agreement supersedes the existing collaboration agreement between Biocon Biologics and FKB for biosimilar Adalimumab, under which Biocon Biologics only had commercialization rights. Commercial production of biosimilar Adalimumab at Biocon Biologics’ facilities will commence following successful technology transfer and regulatory approvals.
Key Highlights
- Biocon Biologics has secured full and exclusive global rights for biosimilar Adalimumab from Fujifilm Kyowa Kirin Biologics Co., Ltd.
- Biocon Biologics will now have end-to-end responsibility for manufacturing, commercialization, and additional development activities.
- The new agreement supersedes the existing collaboration agreement between Biocon Biologics and FKB for biosimilar Adalimumab.
- Commercial production of biosimilar Adalimumab at Biocon Biologics’ facilities will commence following successful technology transfer and regulatory approvals.
- Biocon Biologics initially acquired the commercial rights to biosimilar Adalimumab in 2022 through its acquisition of Viatris’ global biosimilars business.